CUMBERLAND PHARMACEUTICALS INC
CUMBERLAND PHARMACEUTICALS INC (CPIX): 11 pipeline candidates · 3 upcoming catalysts · ~13 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
13.1 months
D/E 2.30 · 0% dilution
Lead: Approved
11 candidates
3 upcoming, next in ~197d
N/A
A transparent, data-derived signal for CUMBERLAND PHARMACEUTICALS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$83.9M
Cash
$11.0M
Quarterly Burn
$4.0M
Runway
13.1 mo
Revenue
$9.1M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (11 candidates)
| Drug | Phase |
|---|---|
| acetadote | — |
| caldolor | Approved |
| Dyscorban® | Phase 2 |
| ifetroban | Phase 2 |
| novel oral therapy targeting fatal form of heart disease in duchenne muscular dystrophy patients | — |
| omeclamox-pak | Approved |
| oral ifetroban | Phase 2 |
| sancuso | Approved |
| Vasculan | Phase 2 |
| Vasculan® | Phase 2 |
Showing 10 of 11 candidates. Sign up for full pipeline.
Upcoming Catalysts (3)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
29
Total value held
$9.3M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 723,518 | $2.4M |
| renaissance technologies llc | 470,696 | $1.5M |
| perceptive advisors llc | 393,956 | $1.3M |
| dimensional fund advisors lp | 276,359 | $898K |
| bridgeway capital management, llc | 163,468 | $531K |
| boothbay fund management, llc | 127,694 | $415K |
| geode capital management, llc | 114,293 | $371K |
| j. goldman & co lp | 81,040 | $263K |
| susquehanna international group, llp | 73,500 | $239K |
| jane street group, llc | 58,907 | $191K |
Showing top 10 of 29 institutional holders of CUMBERLAND PHARMACEUTICALS INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in CUMBERLAND PHARMACEUTICALS INC's pipeline?
CUMBERLAND PHARMACEUTICALS INC (CPIX) has 11 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CUMBERLAND PHARMACEUTICALS INC's next catalyst?
CUMBERLAND PHARMACEUTICALS INC's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: VIBATIV" — expected January 1, 2027.
What is CUMBERLAND PHARMACEUTICALS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CUMBERLAND PHARMACEUTICALS INC has approximately 13.1 months of cash runway.
What is CUMBERLAND PHARMACEUTICALS INC's market capitalization?
CUMBERLAND PHARMACEUTICALS INC's market capitalization is approximately $83.9M.
Who is the CEO of CUMBERLAND PHARMACEUTICALS INC?
Mr. A. J. Kazimi MBA is the chief executive officer of CUMBERLAND PHARMACEUTICALS INC (CPIX).
Get the full picture on CUMBERLAND PHARMACEUTICALS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.